Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Rise in Augmentin adverse reaction reports
medical
GlaxoSmithKline said that it has not altered the manufacture of the product and it is not aware of any batch defects.
Practices encouraged to report all adverse events to the VMD

There has been a significant rise is the number of adverse reaction reports relating to Augmentin Intravenous Powder for Solution for Injection, according to the Veterinary Medicines Directorate (VMD).

In a letter to Veterinary Record (Vol. 176, No. 23) Gillian Diesel from the VMD said that over the past three months, the organisation has seen a 'significantly higher' number of reports relating to Augmentin.

"They all involved hypersensitivity reactions, including allergic oedema, urticaria and allergic pruritus," writes Gillian.

"We notified veterinary practices of a similar issue in 2011 concerning Co-amoxiclav, which also contains amoxicillin and clavulanate."

Augmentin is authorised for use in humans and is authorised for use by veterinary surgeons under the cascade system. It is not authorised for use in animals, so no safety or efficacy studies have been carried out relating to its use in animals.

The VMD spoke to the manufacturer, GlaxoSmithKline and the Medicines and Healthcare Products Regulator Agency (MHRA).

GlaxoSmithKline said that it has not altered the manufacture of the product and is not aware of any batch defects. They asked some practices to send them samples of a batch for testing, which confirmed that the product was within manufacturing specifications.

GlaxoSmithKline and the MHRA also said they were not aware of a rise in the number of reactions or reports from humans relating to the product.

"We would like to encourage practices to report all adverse events to the VMD using our online reporting form," added Gillian.

"As Augmentin is not authorised for use in animals, GlaxoSmithKline has no obligation to investigate these case or report them to the VMD.

"We would also like to remind vets that any human adverse reactions to authorised human medicines should be report to the MHRA."

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.